Ignite Creation Date:
2025-12-25 @ 12:43 AM
Ignite Modification Date:
2026-05-22 @ 3:11 AM
Study NCT ID:
NCT05785767
Status:
RECRUITING
Last Update Posted:
2025-11-21
First Post:
2023-03-14
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
Sponsor:
Regeneron Pharmaceuticals
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
R3767-ONC-2235
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None